Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Transplantation and Cellular Therapy|May 9, 2021
Cellular Therapies for Mantle Cell LymphomaFarah Yassine, Jose Sandoval-Sus, Ernesto Ayala, et al.
Cureus|January 26, 2026
Cytomegalovirus Lymphadenitis After Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T): An Underappreciated Etiology of Hypermetabolic Lymphadenopathy in the Post-CAR-T SettingDaniel Rosas, Alissa Cox, Diana Martinez, et al.
Blood Reviews|November 11, 2017
Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?Alain Mina, Jose Sandoval Sus, Elsa Sleiman, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the LiteratureJulio C Chavez, Jose Sandoval-Sus, Pedro Horna, et al.
Oncology Research and Treatment|October 16, 2023
Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two CentersHayder Saeed, Jose Sandoval-Sus, Franco Castillo-Tokumori, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2020
Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional ExperienceAshley Rose, Ariel Grajales-Cruz, Alex Lim, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution ExperienceJulio C Chavez, Samir Dalia, Jose Sandoval-Sus, et al.
Systematic Reviews|June 5, 2026
Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysisAbat Khan, Hira Habib, Ayesha Imran Butt, et al.
The Lancet. Haematology|December 11, 2024
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trialJuan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
Pageof 3